Clinical Trial Details

Breast Cancer

Radiotherapy Optimization for Low Risk HER-2 Positive Breast Cancer Patients

A Phase III Randomized Trial of Radiotherapy Optimization, Radiation Plus HER2-targeted Therapy Versus HER2-targeted Therapy Alone, for Low-Risk HER2-POSITIVE Breast Cancer (HERO)

Please contact your provider or the research department for full study details.

NCT05705401

Shane Cotter, MD, PhD

Open to Enrollment

research@ridleytreecc.org

(805) 879-0643